PRE-TRANSPLANT CHEMOTHERAPY DOES NOT AFFECT POST TRANSPLANT OUTCOME IN PATIENTS UNDERGOING OHT FOR AL CARDIOMYOPATHY  by Sarswat, Nitasha et al.
Heart Failure and Cardiomyopathies
A884
JACC April 1, 2014
Volume 63, Issue 12
pre-tranSplant cheMotherapy doeS not affect poSt tranSplant outcoMe in patientS 
undergoing oht for al cardioMyopathy
Poster Contributions
Hall C
Sunday, March 30, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Heart Failure and Cardiomyopathies: Therapy IV
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1220-171
Authors: Nitasha Sarswat, Emily Niehaus, Sara Tabtabai, James Stone, Lauren Gilstrap, Matthew Maurer, Ronald Witteles, Jerry Estep, David 
Baran, Mark Zucker, David Seldin, Marc Semigran, Massachusetts General Hospital, Boston, MA, USA
background: Light-chain (AL) cardiac amyloidosis can be treated with cardiac transplantation (HT) followed by high dose melphalan 
chemotherapy and autologous stem cell transplant. We hypothesized that chemotherapy (CTX) prior to HT targeting clonal plasma cell light chain 
production may lead to improved survival after HT.
Methods: We utilized a multinational database from seven cardiac transplant centers, which includes demographic, clinical, hemodynamic and 
therapeutic strategies for patients with heart failure due to AL cardiac amyloidosis.
results: Of 103 patients, 89 (86%) were waitlisted for HT and 56 (64%) survived to HT. 39 (44%) of the waitlisted patients received plasma cell 
targeted chemotherapy with bortezomib, lenalidomide, melphalan, or cyclophosphamide. Chemotherapy use did not differ in waitlisted patients 
that survived to HT (45%) and those that died prior to HT (42%, p=1.0). There were no differences in baseline characteristics between patients 
receiving chemotherapy (+CTX) and those who did not (-CTX). Post HT infection rates were similar in +CTX (21%) and -CTX (14%, p=0.72), while 
renal replacement therapy tended to be less frequent in +CTX patients (29% vs. 8%, p=0.08). Post HT survival was similar in +CTX and -CTX patients 
(Figure).
conclusion: Chemotherapy prior to HT in cardiac amyloid patients with a high plasma light chain burden did not increase post-operative 
infections. Pre and post HT survival was similar in patients receiving chemotherapy to those who did not.
 
